RVL-1201

DRUG4 trials

Sponsors

RVL Pharmaceuticals, Inc.

Conditions

Acquired BlepharoptosisBlepharoptosis

Phase 1

Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis

CompletedNCT01848041

RVL Pharmaceuticals, Inc.Blepharoptosis

Start: 2013-05-31End: 2014-02-28Updated: 2021-11-26

Phase 3

Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

CompletedNCT02436759

RVL Pharmaceuticals, Inc.Acquired Blepharoptosis

Start: 2015-05-31End: 2016-11-30Updated: 2021-10-28

Study of Safety of RVL-1201 in Treatment of Blepharoptosis

CompletedNCT03536949

RVL Pharmaceuticals, Inc.Blepharoptosis

Start: 2018-06-20End: 2019-03-27Updated: 2020-09-16

Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis

CompletedNCT03565887

RVL Pharmaceuticals, Inc.Blepharoptosis

Start: 2018-06-28End: 2019-04-22Updated: 2020-09-16